BACKGROUND: Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBDs) presumably caused by dysregulated immune responses to the gut microbiota. Genetic association studies have implicated dozens of chromosomal regions or loci in IBD susceptibility. The next challenge is to explain the individual role of each of these modest effect loci in the disease state. We have previously identified MAST3 as an IBD susceptibility gene through genetic fine-mapping of the 19p linkage region. Testing MAST3 in a reporter assay provided preliminary evidence that MAST3 modulates the activity of inflammation-related transcription factor nuclear factor kappa B. METHODS: Here we characterized the function of MAST3 through an examination of the influence of the modulation of MAST3 expression on endogenous genome-wide expression patterns. More specifically, we looked at differential gene expression resulting from overexpression and knockdown of the MAST3 gene in epithelial and macrophage cell lines. From we highlight a group of genes whose expression is modulated by MAST3 and correlate their expression with NF-jB activity. Their expression was found to be enriched in inflamed mucosal tissue of UC patients, confirming the importance of these genes in IBD. RESULTS: We highlight a group of genes whose expression is modulated by MAST3 and correlate their expression with NF-κB activity. Their expression was found to be enriched in inflamed mucosal tissue of UC patients, confirming the importance of these genes in IBD. These MAST3-regulated genes are central to mucosal immune responses. Among them are proinflammatory cytokines (e.g., CCL20, IL8), regulators of NF-κB (e.g., TNFAIP3, LY96, NFKBIA), genes involved in interferon-induced defense against pathogen invasion (e.g., IFIT1, ISG15), and genes involved in cell adhesion and/or migration (e.g., CD44, TMOD1). CONCLUSIONS: Taken together, these results confirm MAST3 as a modulator of the inflammatory response through regulation of immune gene expression in the gut of IBD patients.
BACKGROUND:Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBDs) presumably caused by dysregulated immune responses to the gut microbiota. Genetic association studies have implicated dozens of chromosomal regions or loci in IBD susceptibility. The next challenge is to explain the individual role of each of these modest effect loci in the disease state. We have previously identified MAST3 as an IBD susceptibility gene through genetic fine-mapping of the 19p linkage region. Testing MAST3 in a reporter assay provided preliminary evidence that MAST3 modulates the activity of inflammation-related transcription factor nuclear factor kappa B. METHODS: Here we characterized the function of MAST3 through an examination of the influence of the modulation of MAST3 expression on endogenous genome-wide expression patterns. More specifically, we looked at differential gene expression resulting from overexpression and knockdown of the MAST3 gene in epithelial and macrophage cell lines. From we highlight a group of genes whose expression is modulated by MAST3 and correlate their expression with NF-jB activity. Their expression was found to be enriched in inflamed mucosal tissue of UC patients, confirming the importance of these genes in IBD. RESULTS: We highlight a group of genes whose expression is modulated by MAST3 and correlate their expression with NF-κB activity. Their expression was found to be enriched in inflamed mucosal tissue of UC patients, confirming the importance of these genes in IBD. These MAST3-regulated genes are central to mucosal immune responses. Among them are proinflammatory cytokines (e.g., CCL20, IL8), regulators of NF-κB (e.g., TNFAIP3, LY96, NFKBIA), genes involved in interferon-induced defense against pathogen invasion (e.g., IFIT1, ISG15), and genes involved in cell adhesion and/or migration (e.g., CD44, TMOD1). CONCLUSIONS: Taken together, these results confirm MAST3 as a modulator of the inflammatory response through regulation of immune gene expression in the gut of IBD patients.
Authors: S R Targan; S B Hanauer; S J van Deventer; L Mayer; D H Present; T Braakman; K L DeWoody; T F Schaible; P J Rutgeerts Journal: N Engl J Med Date: 1997-10-09 Impact factor: 91.245
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: J P Hugot; M Chamaillard; H Zouali; S Lesage; J P Cézard; J Belaiche; S Almer; C Tysk; C A O'Morain; M Gassull; V Binder; Y Finkel; A Cortot; R Modigliani; P Laurent-Puig; C Gower-Rousseau; J Macry; J F Colombel; M Sahbatou; G Thomas Journal: Nature Date: 2001-05-31 Impact factor: 49.962
Authors: H C Reinecker; M Steffen; T Witthoeft; I Pflueger; S Schreiber; R P MacDermott; A Raedler Journal: Clin Exp Immunol Date: 1993-10 Impact factor: 4.330
Authors: Virginie Mercier; Gabrielle Boucher; Dominic Devost; Kyla Bourque; Azadeh Alikashani; Claudine Beauchamp; Alain Bitton; Sylvain Foisy; Philippe Goyette; Guy Charron; Terence E Hébert; John D Rioux Journal: Cell Signal Date: 2022-02-24 Impact factor: 4.850
Authors: Robert L Whitener; Lisa Gallo Knight; Jianwei Li; Sarah Knapp; Shuyao Zhang; Mani Annamalai; Vadim M Pliner; Dongtao Fu; Ilian Radichev; Christina Amatya; Alexei Savinov; Arif Yurdagul; Shuai Yuan; John Glawe; Christopher G Kevil; Jing Chen; Scott E Stimpson; Clayton E Mathews Journal: J Immunol Date: 2017-11-06 Impact factor: 5.422
Authors: Ann Elisabet Østvik; Tarjei Dahl Svendsen; Atle van Beelen Granlund; Berit Doseth; Helene Kolstad Skovdahl; Ingunn Bakke; Silje Thorsvik; Wahida Afroz; Gunnar Andreas Walaas; Tom Eirik Mollnes; Björn Inge Gustafsson; Arne Kristian Sandvik; Torunn Bruland Journal: J Crohns Colitis Date: 2020-07-30 Impact factor: 9.071
Authors: Egidio Spinelli; Kyle R Christensen; Emily Bryant; Amy Schneider; Jennifer Rakotomamonjy; Alison M Muir; Jessica Giannelli; Rebecca O Littlejohn; Elizabeth R Roeder; Berkley Schmidt; William G Wilson; Elysa J Marco; Kazuhiro Iwama; Satoko Kumada; Tiziana Pisano; Carmen Barba; Annalisa Vetro; Eva H Brilstra; Richard H van Jaarsveld; Naomichi Matsumoto; Hadassa Goldberg-Stern; Patrick W Carney; P Ian Andrews; Christelle M El Achkar; Sam Berkovic; Lance H Rodan; Kirsty McWalter; Renzo Guerrini; Ingrid E Scheffer; Heather C Mefford; Simone Mandelstam; Linda Laux; John J Millichap; Alicia Guemez-Gamboa; Angus C Nairn; Gemma L Carvill Journal: Ann Neurol Date: 2021-07-13 Impact factor: 11.274